Purevax RCPCh Lyophilisate and Solvent for Suspension for Injection

Cats
Common
(1 to 10 animals / 100 animals
treated):
Transient apathy, anorexia, and
hyperthermia
(observed during
safety and field studies).
Injection site reactions (slight pain
at palpation, itching or limited
oedema)
(observed during safety
and field studies)
Uncommon
(1 to 10 animals / 1,000 animals
treated):
Hypersensitivity reaction
(observed in field studies)
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Emesis
; transient hyperthermia
and lethargy, sometimes
associated with lameness
(based
on post-marketing experience)
lasting usually for 1 or 2 days
disappearing within 1 or 2 weeks at most
may require appropriate symptomatic treatment
mostly within 24 to 48 hours

Revised: March 2023
AN: 00563/2022
observed 1 to 3 weeks following booster vaccination in adult cats
Reporting adverse events is important. It allows continuous safety monitoring of
a veterinary medicinal product. Reports should be sent, preferably via a
veterinarian, to either the marketing authorisation holder or its local
representative or the national competent authority via the national reporting
system. See also the last section of the package leaflet for respective contact
details.